Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 02, 2021 08:00 ET | Source: Chiasma

Chiasma to Participate in the H.C. Wainwright Global Life Sciences Conference

NEEDHAM, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company, today announced that management will present a company overview at the...
February 25, 2021 08:00 ET | Source: Chiasma

Chiasma to Report Fourth Quarter 2020 Results on March 4

NEEDHAM, Maine, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a conference call and live audio...
January 19, 2021 07:00 ET | Source: Chiasma

Chiasma Announces Hiring of John Doyle as Chief Financial Officer

NEEDHAM, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize...
January 06, 2021 16:01 ET | Source: Chiasma

Chiasma Provides Corporate Update and Previews Expected 2021 Milestones

MYCAPSSA® launch in US continuing to gain traction with physicians, patients, and payers MYCAPSSA® EMA submission for EU marketing approval on track for mid-2021 following positive results of...
November 23, 2020 08:00 ET | Source: Chiasma

Chiasma to Participate in Two Investor Conferences in December

NEEDHAM, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize...
November 20, 2020 08:00 ET | Source: Chiasma

Chiasma to Host an Expert Panel on Acromegaly and the MPOWERED® Phase 3 Trial Results

NEEDHAM, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize...
November 18, 2020 07:00 ET | Source: Chiasma

Chiasma Announces Positive Topline Results from the MPOWERED™ Phase 3 Clinical Trial Comparing MYCAPSSA® (octreotide capsules) to Long Acting Injectables for the Maintenance Treatment of Adults with Acromegaly

91% of patients on MYCAPSSA maintained IGF-1 response in the 9-month randomized, controlled phase of the non-inferiority trial Company intends to submit a marketing application for MYCAPSSA in the EU...
November 16, 2020 08:00 ET | Source: Chiasma

Chiasma to Participate in the Jefferies Virtual London Healthcare Conference

NEEDHAM, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize...
November 05, 2020 16:05 ET | Source: Chiasma

Chiasma Reports Third Quarter 2020 Results and Provides MYCAPSSA Launch Update

Launched MYCAPSSA® in U.S. earlier than expected and recognized first net product revenues in September Well capitalized to support the MYCAPSSA launch On track to announce MPOWERED™ Phase 3 trial...
October 30, 2020 08:00 ET | Source: Chiasma

Chiasma Reinforces Commitment to People with Acromegaly and Advocacy Organizations on Acromegaly Awareness Day

NEEDHAM, Mass., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA) today recognizes Acromegaly Awareness Day, which is observed every year on November 1, and reiterates its commitment to...